LYA914 is an orally active AR/AR-V7 PROTAC degrader. It targets the proteolysis of the androgen receptors (AR) conserved DNA-binding domain (DBD). LYA914 demonstrates effective antiproliferative activity in Enzalutamide-insensitive or resistant cells and inhibits tumor growth in VCaP/LNCaP tumor mouse models. It is suitable for studying castration-resistant prostate cancer (CRPC).
Target:
PROTACs|||Androgen Receptor|||Akt
* VAT and and shipping costs not included. Errors and price changes excepted
